Evidence map›Paper›PMID 36464325›Full record

ReviewCancer reports (Hoboken, N.J.)2023

Identifying monoclonal gammopathy of undetermined significance from electronic health records.

Hilary C Tanenbaum, Brenda M Birmann, Kimberly A Bertrand, Lauren R Teras, Amrita Y Krishnan, Hoda Pourhassan, Scott Goldsmith, Kimberly Cannavale, Sophia S Wang, Chun R Chao

Open access · goldFull text readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer reports (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Hilary C TanenbaumDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID 0000-0003-2282-1662
Brenda M BirmannChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Kimberly A BertrandSlone Epidemiology Center, Boston University, Boston, Massachusetts, USA.
Lauren R TerasIntramural Research Department, American Cancer Society, Atlanta, Georgia, USA.
Amrita Y KrishnanCity of Hope Medical Center, California, USA.
Hoda PourhassanCity of Hope Medical Center, California, USA.
Scott GoldsmithCity of Hope Medical Center, California, USA.
Kimberly CannavaleDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
Sophia S WangCity of Hope Medical Center, California, USA.
Chun R ChaoDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID 0000-0002-6072-4954
City Of Hope National Medical Center · USKaiser Permanente · USAmerican Cancer Society · USBoston University · USBrigham and Women's Hospital · US

Funding

Risk factors for molecular subtypes of NHL a prospective evaluationR01CA202712 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BIRMANN, BRENDA M, WANG, SOPHIA S. · 2016 to 2020
$3.7M
NCI NIH HHS R01 CA202712
6 · The paper itself

Abstract

backgroundMonoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM). Use of electronic health records may facilitate large-scale epidemiologic research to elucidate risk factors for the progression of MGUS to MM or other lymphoid malignancies.

aimsWe evaluated the accuracy of an electronic health records-based approach for identifying clinically diagnosed MGUS cases for inclusion in studies of patient outcomes/ progression risk. METHODS AND

resultsData were retrieved from Kaiser Permanente Southern California's comprehensive electronic health records, which contain documentation of all outpatient and inpatient visits, laboratory tests, diagnosis codes and a cancer registry. We ascertained potential MGUS cases diagnosed between 2008 and 2014 using the presence of an MGUS ICD-9 diagnosis code (273.1). We initially excluded those diagnosed with MM within 6 months after MGUS diagnosis, then subsequently those with any lymphoid malignancy diagnosis from 2007 to 2014. We reviewed medical charts for 100 randomly selected potential cases for evidence of a physician diagnosis of MGUS, which served as our gold standard for case confirmation. To assess sensitivity, we also investigated the presence of the ICD-9 code in the records of 40 randomly selected and chart review-confirmed MGUS cases among patients with a laboratory report of elevated circulating monoclonal (M-) protein (a key test for MGUS diagnosis) and no subsequent lymphoid malignancy (as described above). The positive predictive value (PPV) for the ICD-9 code was 98%. All MGUS cases confirmed by chart review also had confirmatory laboratory test results. Of the confirmed cases first identified via M-protein test results, 88% also had the ICD-9 diagnosis code.

conclusionThe diagnosis code-based approach has excellent PPV and likely high sensitivity for detecting clinically diagnosed MGUS. The generalizability of this approach outside an integrated healthcare system warrants further evaluation.

Indexed as

Monoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaElectronic Health RecordsHumansPredictive Value of TestsRisk Factorscase identificationdiagnosis codeelectronic health recordsMGUSmonoclonal gammopathy of undetermined significance

Identifiers

PMID36464325
PMCPMC10026307
OpenAlexW4310664030

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read34
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.